Prognica Labs and NextGen Immuno Therapeutics Announce Partnership to Advance AI-Driven Precision Immunology
Collaboration targets AI-powered immune diagnostics, translational research, and real-world data solutions across high-growth healthcare markets
Prognica Labs and NextGen Immuno Therapeutics have announced a strategic partnership to accelerate the development and deployment of AI-powered immune diagnostics and precision medicine solutions. The collaboration brings together advanced immune profiling and artificial intelligence to support earlier disease detection, improved patient stratification, and more informed clinical decision-making.
Headquartered in Dubai and Vienna respectively, the two companies will focus on expanding precision immunology capabilities across high-growth healthcare markets, including the Gulf Cooperation Council, India, and the United States. The partnership reflects increasing global demand for diagnostic platforms capable of translating complex biological data into clinically actionable insights.
Combining immune profiling and AI analytics
The partnership integrates NextGen Immuno Therapeutics’ immune profiling platform with Prognica Labs’ AI-driven analytics infrastructure. NextGen’s technology analyses immune system signals from blood samples to generate patient-specific insight reports, enabling clinicians to assess disease risk, guide treatment selection, and monitor therapeutic response.
Prognica Labs will enhance these capabilities by applying AI-based predictive modelling, real-world evidence generation, and health data integration. Together, the companies aim to provide healthcare providers and pharmaceutical partners with more precise diagnostic tools while strengthening the evidence base required for regulatory and clinical adoption.
Khalid Shaikh, Founder & CEO of Prognica Labs, said:
“The future of drug discovery lies in precision, not probability. This partnership bridges translational immunology with AI-powered decision systems. In markets like GCC, India, and the United States, where oncology burden is rising sharply, we are building not just a diagnostic solution - but an ecosystem for early detection, patient stratification, and cost-efficient care delivery.”
Expanding precision immunology across healthcare systems
The collaboration will support the deployment of immune diagnostics across hospital networks, transplant centres, cancer institutes, and public health programmes. By combining AI with immune profiling, the partnership seeks to enable earlier clinical intervention and reduce uncertainty in treatment selection, particularly in oncology and immune-mediated diseases.
Dr. Ram Vinay Pandey, Founder & CEO of NextGen Immuno Therapeutics, said:
“Immune profiling is the missing layer in personalized medicine. Our platform translates complex immunological signals into clinically actionable insights. By partnering with Prognica Labs, we are accelerating our mission to move from isolated clinical pilots to scalable global deployment - bringing immune foresight to medicine before it’s too late.”
The ability to convert immune system data into predictive insights has implications not only for individual patient care, but also for clinical trial design and therapeutic development. Immune biomarkers can help identify which patients are most likely to respond to treatment, improving clinical outcomes while reducing development timelines and costs.
Supporting drug development, clinical research, and public health
The partnership also aims to strengthen translational research by integrating immune data with AI-driven analytics. This approach enables pharmaceutical companies and healthcare providers to better understand disease progression, optimise treatment pathways, and generate real-world evidence to support regulatory and commercial strategies.
Dr. Sujay Patil, Chief Scientific Officer at Prognica Labs, said:
“From a scientific standpoint, integrating immune profiling with advanced AI analytics represents a paradigm shift in how we approach oncology and immune-mediated diseases. Immune signatures provide early biological signals long before clinical deterioration becomes evident. By combining high-dimensional immunological data with predictive modeling, we can improve patient stratification, reduce therapeutic trial-and-error, and generate real-world evidence that strengthens both clinical decision-making and regulatory confidence.”
Positioning precision immunology for global scale
Healthcare systems worldwide are increasingly investing in data-driven infrastructure and precision medicine approaches. The integration of AI with immune diagnostics offers a pathway to more proactive and personalised care, particularly in oncology, transplant medicine, and autoimmune disease management.
By combining advanced immunology platforms with scalable AI infrastructure, Prognica Labs and NextGen Immuno Therapeutics are positioning their partnership at the intersection of diagnostics, therapeutics, and digital health. As healthcare providers and pharmaceutical companies seek more precise tools to guide treatment and accelerate development, integrated immune intelligence platforms are expected to play an increasingly central role in the future of medicine.
Author
BioFocus Newsroom